Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “QL1706”

131 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 131 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07005583
What this trial is testing

Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer

Who this might be right for
Triple-Negative Breast Cancer (TNBC)
Tianjin Medical University Cancer Institute and Hospital 46
Testing effectiveness (Phase 2)UnknownNCT06509971
What this trial is testing

QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Who this might be right for
Platinum-resistant Recurrent Ovarian Cancer
West China Second University Hospital 39
Not applicableNot Yet RecruitingNCT07187674
What this trial is testing

The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel

Who this might be right for
Triple Negative Breast Cancer (TNBC)
Harbin Medical University 20
Testing effectiveness (Phase 2)Looking for participantsNCT07601178
What this trial is testing

QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer

Who this might be right for
TNBC, Triple Negative Breast Cancer
Jiangsu Cancer Institute & Hospital 34
Testing effectiveness (Phase 2)UnknownNCT05179317
What this trial is testing

Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy With or Without Bevacizumab in Women With Recurrent, or Metastatic Cervical Cancer

Who this might be right for
Cervical Cancer
Qilu Pharmaceutical Co., Ltd. 60
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07446387
What this trial is testing

A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer (CRC)
Jiangsu Cancer Institute & Hospital 70
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07009145
What this trial is testing

QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC

Who this might be right for
Unresectable Colorectal CancerMetastatic Colorectal Cancer (CRC)MSI-H/dMMR Colorectal Cancer
Qianfoshan Hospital 22
Large-scale testing (Phase 3)Active Not RecruitingNCT05690945
What this trial is testing

QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer
Qilu Pharmaceutical Co., Ltd. 606
Testing effectiveness (Phase 2)Looking for participantsNCT07315854
What this trial is testing

Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

Who this might be right for
Gastric Cancer (GC)Gastroesophageal Junction CancerAdvanced Gastric Cancer+1 more
Beijing Friendship Hospital 32
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07828873
What this trial is testing

A Single-Arm Study of QL1706 Combined With DOS as Neoadjuvant Therapy for Locally Advanced Gastric/GEJ Adenocarcinoma

Who this might be right for
Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
The First Affiliated Hospital of Zhengzhou University 34
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07533305
What this trial is testing

Efficacy and Safety of QL1706 Combined With Nab-paclitaxel and Cisplatin as 1st Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Who this might be right for
QL1706ESCCFirst-line Therapy
The First Affiliated Hospital of Henan University of Science and Technology 50
Very early researchNot Yet RecruitingNCT06931873
What this trial is testing

Neoadjuvant Radiochemotherapy Combined With QL1706 for Low Rectal Cancer

Who this might be right for
Rectal Cancer
Changhai Hospital 60
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07663513
What this trial is testing

Iparomlimab and Tovorilimab (QL1706) Combined With Bevacizumab and Chemotherapy as Neoadjuvant Therapy for Advanced Ovarian Cancer

Who this might be right for
Ovarian Cancers
Fudan University 36
Large-scale testing (Phase 3)Looking for participantsNCT06749899
What this trial is testing

QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

Who this might be right for
Nasopharyngeal Cancinoma (NPC)Nasopharyngeal Cancer
Sun Yat-Sen University Cancer Center 580
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07113964
What this trial is testing

QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)

Who this might be right for
Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency
The First Affiliated Hospital with Nanjing Medical University 79
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07617818
What this trial is testing

QL1706 Combined With Cisplatin/Paclitaxel as Neoadjuvant Therapy for Cervical Cancer

Who this might be right for
Cervical CancerNeoadjuvant TherapyImmunotherapy
Second Affiliated Hospital, Zhejiang University, School of Medicine 50
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07283991
What this trial is testing

QL1706 Plus Chemotherapy for Borderline Resectable Esophageal Cancer

Who this might be right for
Esophageal Cancer
Ruijin Hospital 24
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07246317
What this trial is testing

Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer

Who this might be right for
Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 188
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07416058
What this trial is testing

PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC

Who this might be right for
Lung Adenocarcinoma
Guangdong Association of Clinical Trials 61
Large-scale testing (Phase 3)Looking for participantsNCT05487391
What this trial is testing

QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Qilu Pharmaceutical Co., Ltd. 632
Next Page